21892-60-4

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(4-BROMOPHENYL)-2-NITROPROPENE is used as an intermediate in the synthesis of various organic molecules, particularly in the pharmaceutical industry. Its unique structure allows for the creation of biologically active compounds, contributing to the development of new drugs and therapies.
Used in Agrochemical Production:
In the agrochemical industry, 1-(4-BROMOPHENYL)-2-NITROPROPENE is utilized as a key component in the synthesis of various agrochemicals. Its role as an intermediate aids in the production of compounds that can be used in the development of pesticides, herbicides, and other agricultural chemicals to improve crop yield and protect against pests.

Upstream product

• 79-24-3 Nitroethane 
• 1122-91-4 4-bromo-benzaldehyde 
• 64-18-6 formic acid 
• 75-52-5 nitromethane 
• 631-61-8 ammonium acetate 
• 135711-48-7 [1-(4-Bromo-phenyl)-2-nitro-propyl]-butyl-amine 
• 141-43-5 ethanolamine 

Downstream Products

• 13235-83-1 (±)-1-(4-bromophenyl)propan-2-amine 
• 103675-99-6 p-bromophenylacetone oxime 
• 93564-56-8 N-hydroxy-p-bromoamphetamine 
• 13213-36-0 1-phenylpropan-2-one oxime 
• 104736-34-7 (Z)-1-(4-bromophenyl)-2-propanone oxime 
• 104749-39-5 (E)-1-(4-bromophenyl)-2-propanone oxime 
• 135711-48-7 [1-(4-Bromo-phenyl)-2-nitro-propyl]-butyl-amine 
• 69358-82-3 2-[2-(4-Bromo-phenyl)-1-methyl-ethylidene]-malononitrile 
• 1306633-96-4 5-(4-bromophenyl)-4-methyl-2-phenylthiazole 
• 1306633-99-7 5-(4-bromophenyl)-2-(4-methoxyphenyl)-4-methylthiazole 
• 1397266-35-1 (1S,2R)-1-(2-chlorophenyl)-2-nitropropyl ethanethioate 
• 1519057-30-7 3-(4-bromophenyl)-2,6,6-trimethyl-1-phenyl-1,5,6,7-tetrahydro-4H-indol-4-one 
• 1519057-72-7 3-(4-bromophenyl)-2-methyl-1-phenyl-1,5,6,7-tetrahydro-4H-indol-4-one 
• 1233524-85-0 methyl (1-(4-bromophenyl)propan-2-yl)carbamate 

Relevant academic research and scientific papers

Protein arginine methyltransferase 5 (PRMT5) inhibitor, pharmaceutical products thereof, and methods thereof

The present invention provides a PRMT5 inhibitor of formula (I); R1 is a non-hydrogen monovalent group; W is a direct bond or-NH-; T, U and V are independently from each other selected from C and N; R2 is H or halogen; m is 1 or 2; X is carbon, nitrogen or oxygen; Y is C or N; Z is a direct bond or carbon; R3 is H, a non-hydrogen monovalent group, an oxo group, a divalent spiro-forming group or adivalent bridge-forming group; and n is 1 or 2, and represents a single or double bond. The present invention also provides pharmaceutical products comprising the PRMT5 inhibitor and use thereof in the treatment of proliferative disorders such as cancer, metabolic disorders, hematological disorders, autoimmune diseases and inflammatory diseases.

A diversity-oriented synthesis of polyheterocycles: Via the cyclocondensation of azomethine imine

Pd-Catalyzed sequential reactions to afford skeletally diverse molecules are described. The reaction involved azomethine imine formation and a cyclocondensation reaction as individual steps. The methodology provides excellent regio- and stereocontrol. Skeletal diversity was ensured by changing the electrophilic counterpart of azomethine imine. Due to its broader diversity and complexity, the DOS methodology is likely to benefit drug discovery and development in the future.

INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF

The present invention provides PRMT5 inhibitors of Formula (I), wherein R1 is a non-hydrogen monovalent group; W is a direct bond or -NH-; T, U, and V are independently of each other selected from C and N; R2 is H or a halo; m is 1 or 2; X is a carbon, a nitrogen, or an oxygen; Y is C or N; Z is a direct bond or a carbon; R3 is H, a non-hydrogen monovalent group, an oxo group, a bivalent spiro ring-forming group, or a bivalent bridge-forming group; n is 1 or 2; and Formula (II) stands for a single bond or a double bond. Pharmaceutical products comprising the PRMT5 inhibitors and use thereof in treating proliferative disorders such as cancer, metabolic disorders, blood disorders, autoimmune diseases, and inflammatory diseases are also provided.

Inhibition of LDL oxidation and inflammasome assembly by nitroaliphatic derivatives. Potential use as anti-inflammatory and anti-atherogenic agents

We have previously shown the antioxidant and anti-inflammatory properties of several para-substituted arylnitroalkenes. Since oxidative stress and inflammation are key processes that drive the initiation and progression of atherosclerosis, in the present work the antioxidant, anti-inflammatory and anti-atherogenic properties of an extended library of aryl-nitroaliphatic derivatives, including several newly designed nitroalkanes, was explored. The antioxidant capacity of the nitroaliphatic compounds, measured using the oxygen radical absorbance capacity assay (ORAC) showed that the p-methylthiophenyl-derivatives were about three times more effective than Trolox to prevent fluorescein oxidation, independently of the presence or the absence of the double bond next to the nitro group. The peroxyl radical scavenger capacity of the p-dimethylaminophenyl-derivatives was even higher, being the reduced form of these compounds even more active. In fact, while the antioxidant capacity of 1-dimethylamino-4-(2-nitro-1Z-ethenyl)benzene and 1-dimethylamino-4-(2-nitro-1Z-propenyl)benzene was 4.2 ± 0.1 and 5.4 ± 0.1 Trolox Eq/mol, respectively; ORAC values obtained with the ethyl and the propyl derivatives were 10 ± 1 and 13 ± 2 Trolox Eq/mol, respectively. The p-dimethylamino-derivatives, especially the nitroalkanes, were also able to prevent LDL oxidation mediated by peroxyl radicals. Oxygen consumption due to the oxidation of fatty acids was delayed in the presence of the dimethylamino substituted compounds, only the alkanes interrupted the chain of lipid oxidations decreasing the rate of oxygen consumption. Although the formation of foam cells in the presence of oxidized-LDL (oxLDL) remained unaffected, the molecules containing the dimethylamino moiety were able to decrease the expression of IL-1β in LPS/INF-γ challenged macrophages.

PROCESS FOR THE PREPARATION OF LACTAMS FROM GLYOXYLIC ACID

A process for the synthesis of lactams suitable for use in antimicrobial, anti-biofilm bacteriostatic compositions.

Arylnitroalkenes as scavengers of macrophage-generated oxidants

Oxygen and nitrogen derived molecules mediated oxidation and nitration have been involved in several pathological conditions. Conversely, nitric oxide and hydrogen peroxide are important signalization intermediates, whose concentrations are tightly regula

Iron-catalyzed tandem one-pot addition and cyclization of the blaise reaction intermediate and nitroolefins: Synthesis of substituted NH-pyrroles from nitriles

The iron-catalyzed addition and cyclization of the Blaise reaction intermediate and nitroolefins to synthesize highly functionalized NH-pyrroles in a tandem one-pot manner from nitriles has been developed. This reaction shows good functional group tolerance and affords a broad spectrum of substituted NH-pyrroles in good yields. Copyright

Highly enantioselective reduction of α-methylated nitroalkenes

Highly selective: The reduction of α-methyl-substituted nitroalkenes succeeds in a highly enantioselective fashion with an ene reductase from Gluconobacter oxydans. Under optimized reaction conditions the desired nitroalkanes are formed with enantiomeric excesses of up to 95% in these biotransformations. Copyright

Enzymatic enantiomeric resolution of phenylethylamines structurally related to amphetamine

Both enantiomers of several phenylethylamines, structurally related to amphetamine, have been prepared in good yields and excellent enantiomeric purity by enzymatic kinetic resolution using CAL-B and ethyl methoxyacetate as the acyl donor. In the case of the 4-hydroxyderivative of amphetamine (compound 4i), the S enantiomer racemized possibly in a dynamic kinetic resolution (DKR) under the enzymatic conditions used. The Royal Society of Chemistry 2011.

ORTHO AMINOAMIDES FOR THE TREATMENT OF CANCER

Compounds of formula are HDAC inhibitors. These compounds are useful for the treatment of diseases such as cancer in humans or animals.